RT Journal Article
SR Electronic
T1 Outbreak analysis with a logistic growth model shows COVID-19 suppression dynamics in China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.25.20043539
DO 10.1101/2020.03.25.20043539
A1 Zou, Yi
A1 Pan, Stephen
A1 Zhao, Peng
A1 Han, Lei
A1 Wang, Xiaoxiang
A1 Hemerik, Lia
A1 Knops, Johannes
A1 van der Werf, Wopke
YR 2020
UL http://medrxiv.org/content/early/2020/04/15/2020.03.25.20043539.abstract
AB China reported a major outbreak of a novel coronavirus, SARS-CoV2, from mid-January till mid-March 2020. The number of cases outside China is now growing fast, while in mainland China the virus outbreak is largely under control. We review the epidemic virus growth and decline curves in China using a phenomenological logistic growth model to summarize the outbreak dynamics using three parameters that characterize the epidemic’s timing, rate and peak. During the initial phase, the number of virus cases doubled every 2.7 (range 2.2 - 4.4) days. The rate of increase in the number of reported cases peaked approximately 10 days after suppression measures were started on 23-25 January 2020. The peak in the number of reported sick cases occurred on average 18 days after the start of measures. From the time of starting measures till the peak, the number of cases increased by a factor 39 in the province Hubei, and by a factor 9.5 for all of China (range: 6.2-20.4 in the other provinces). Complete suppression took up to 2 months (range: 23-57d.), during which period severe restrictions, social distancing measures, testing and isolation of cases were in place. The suppression of the disease in China has been successful, demonstrating that suppression is a viable strategy to contain SARS-CoV2.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAFunding StatementNo external funding was receivedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in this paper were publicly accessible and have been described in the manuscript